- Home
- SNAX vs TNFA Comparison
SNAX vs TNFA Comparison
Compare SNAX & TNFA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNAX
- TNFA
- Stock Information
- Founded
- SNAX 2017
- TNFA 2014
- Country
- SNAX United States
- TNFA United States
- Employees
- SNAX N/A
- TNFA N/A
- Industry
- SNAX Packaged Foods
- TNFA
- Sector
- SNAX Consumer Staples
- TNFA
- Exchange
- SNAX Nasdaq
- TNFA NYSE
- Market Cap
- SNAX 2.7M
- TNFA 3.2M
- IPO Year
- SNAX N/A
- TNFA N/A
- Fundamental
- Price
- SNAX $0.75
- TNFA $1.16
- Analyst Decision
- SNAX
- TNFA
- Analyst Count
- SNAX 0
- TNFA 0
- Target Price
- SNAX N/A
- TNFA N/A
- AVG Volume (30 Days)
- SNAX 128.6K
- TNFA 297.1K
- Earning Date
- SNAX 11-13-2024
- TNFA 11-14-2024
- Dividend Yield
- SNAX N/A
- TNFA N/A
- EPS Growth
- SNAX N/A
- TNFA N/A
- EPS
- SNAX N/A
- TNFA N/A
- Revenue
- SNAX $19,364,939.00
- TNFA N/A
- Revenue This Year
- SNAX $30.31
- TNFA N/A
- Revenue Next Year
- SNAX N/A
- TNFA N/A
- P/E Ratio
- SNAX N/A
- TNFA N/A
- Revenue Growth
- SNAX N/A
- TNFA N/A
- 52 Week Low
- SNAX $0.55
- TNFA $1.05
- 52 Week High
- SNAX $2.33
- TNFA $5.91
- Technical
- Relative Strength Index (RSI)
- SNAX 50.42
- TNFA 44.65
- Support Level
- SNAX $0.70
- TNFA $1.12
- Resistance Level
- SNAX $0.77
- TNFA $1.52
- Average True Range (ATR)
- SNAX 0.08
- TNFA 0.12
- MACD
- SNAX 0.01
- TNFA -0.00
- Stochastic Oscillator
- SNAX 45.54
- TNFA 12.20
About SNAX Stryve Foods Inc.
Stryve Foods Inc is a healthy snacking company that manufactures, markets, and sells differentiated healthy snacking products. The company offers convenient snacks that are lower in sugar and carbohydrates and higher in protein than other snacks.
About TNFA TNF PHARMACEUTICALS INC EFFEC
TNF Pharmaceuticals Inc is a clinical-stage pharmaceutical company committed to extending a healthy lifespan. The company is developing and commercializing two therapeutic platforms. MyMD-1 is a small molecule that regulates the immunometabolic system to treat autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. It is being developed to treat age-related illnesses such as frailty and sarcopenia. Supera-CBD is a synthetic derivative of CBD being developed to treat various conditions, including epilepsy, pain, and anxiety/depression, through its effects on the CB2 receptor, opioid receptors, and monoamine oxidase enzyme type B.